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Introduction {#jdi13125-sec-0005}
============

The appropriate management of elderly Japanese patients with type 2 diabetes mellitus is of great importance and a topical issue. In 2016, the Ministry of Health, Labour and Welfare in Japan announced that approximately 10 million people were suspected to have type 2 diabetes mellitus[1](#jdi13125-bib-0001){ref-type="ref"}. The proportion of these people who are aged ≥60 years is increasing for both men and women[1](#jdi13125-bib-0001){ref-type="ref"}.

The treatment of elderly patients with type 2 diabetes mellitus is complex. The difficulties lie in the clinical, mental and functional heterogeneity of elderly patients with type 2 diabetes mellitus[2](#jdi13125-bib-0002){ref-type="ref"}, [3](#jdi13125-bib-0003){ref-type="ref"}, [4](#jdi13125-bib-0004){ref-type="ref"}, [5](#jdi13125-bib-0005){ref-type="ref"}, [6](#jdi13125-bib-0006){ref-type="ref"}. For example, elderly patients with type 2 diabetes mellitus have numerous comorbidities and difficulties, such as diabetic complications, including micro‐ and macrovascular diseases, cognitive impairment, urinary incontinence, sarcopenia, and increased fall risk[5](#jdi13125-bib-0005){ref-type="ref"}, [6](#jdi13125-bib-0006){ref-type="ref"}, [7](#jdi13125-bib-0007){ref-type="ref"}; consequently, the management of these might necessitate polypharmacy. Polypharmacy can be problematic, as it increases the risk of adverse drug events[8](#jdi13125-bib-0008){ref-type="ref"}, [9](#jdi13125-bib-0009){ref-type="ref"}, drug--drug interactions[10](#jdi13125-bib-0010){ref-type="ref"}, [11](#jdi13125-bib-0011){ref-type="ref"} and falls[6](#jdi13125-bib-0006){ref-type="ref"}, [12](#jdi13125-bib-0012){ref-type="ref"}, and raises treatment costs[13](#jdi13125-bib-0013){ref-type="ref"}.

Among the various pharmacological treatments for type 2 diabetes mellitus, such as oral antidiabetic drugs (OADs), insulins and glucagon‐like peptide 1 receptor agonists, sodium--glucose cotransporter 2 (SGLT2) inhibitors have emerged as a comparatively new class of OADs. Tofogliflozin hydrate (Apleway^®^; Sanofi K.K., Tokyo, Japan; and Deberza^®^; Kowa Company, Ltd., Nagoya, Japan) is an SGLT2 inhibitor that was approved in Japan in 2014 for the treatment of type 2 diabetes mellitus[14](#jdi13125-bib-0014){ref-type="ref"}, [15](#jdi13125-bib-0015){ref-type="ref"}. The safety and effectiveness of tofogliflozin have been shown in previous clinical trials and studies[16](#jdi13125-bib-0016){ref-type="ref"}, [17](#jdi13125-bib-0017){ref-type="ref"}, [18](#jdi13125-bib-0018){ref-type="ref"}, [19](#jdi13125-bib-0019){ref-type="ref"}.

The insulin‐independent mechanism of SGLT2 inhibitors carries a low risk of hypoglycemia, and leads to the reduction of glycated hemoglobin (HbA1c) and bodyweight. However, the unique mechanism of SGLT2 inhibitors also contributes to urinary tract and genital infections, and events resulting from dehydration, all of which are now well‐known adverse drug reactions (ADRs) of SGLT2 inhibitors. Owing to these ADRs, a post‐marketing study was planned before approval, as part of the risk management plan[20](#jdi13125-bib-0020){ref-type="ref"}, [21](#jdi13125-bib-0021){ref-type="ref"}. Strong concerns about the safety of SGLT2 inhibitors have been indicated by the recommendation for SGLT2 inhibitor use, which was first issued by experts in 2014, shortly after the launch of SGLT2 inhibitors[22](#jdi13125-bib-0022){ref-type="ref"}, [23](#jdi13125-bib-0023){ref-type="ref"}. This recommendation warned that SGLT2 inhibitors should be used with caution in elderly patients, and further stated that all patients aged ≥65 years with type 2 diabetes mellitus who started to receive these drugs within 3 months after their launch should be registered for inclusion in a post‐marketing study[22](#jdi13125-bib-0022){ref-type="ref"}. Studies of elderly patients were required not only because of the recommendation, but also because of the scarcity of available information on the safety and effectiveness of SGLT2 inhibitors, including tofogliflozin, in elderly patients, because pre‐approval clinical trials mainly included non‐elderly patients with type 2 diabetes mellitus for the evaluation of safety concerns.

Thus, we carried out a 1‐year post‐marketing study of tofogliflozin in elderly Japanese patients (aged ≥65 years) in real‐world settings (Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly \[J‐STEP/EL\]). We have previously reported the overall results of safety and effectiveness[24](#jdi13125-bib-0024){ref-type="ref"}, [25](#jdi13125-bib-0025){ref-type="ref"}. As information on the safety and effectiveness in relation to the number of OADs and the use of insulin are clinically important for type 2 diabetes mellitus management and future therapeutic strategy, we carried out a subanalysis of the J‐STEP/EL study data[25](#jdi13125-bib-0025){ref-type="ref"} to further assess the safety and effectiveness of tofogliflozin by categorizing patients by the number of OADs and the use of insulin at baseline. Herein, we report the results of this subanalysis.

Methods {#jdi13125-sec-0006}
=======

Study design {#jdi13125-sec-0007}
------------

The details of the study are available elsewhere[25](#jdi13125-bib-0025){ref-type="ref"}. In brief, this was a prospective, observational and multicenter post‐marketing study carried out in Japan. Patients were enrolled between 23 May 2014 and 22 August 2014, and followed for 1 year (52 weeks) from the date of tofogliflozin initiation. Sanofi K.K. and Kowa Company, Ltd. co‐sponsored this study.

We carried out the present study in compliance with the ethical principles of the Declaration of Helsinki, and the Japanese authorized standards for post‐marketing surveillance, Good Post‐marketing Study Practice, without intervening in the dosage and administration of tofogliflozin. Because Good Post‐marketing Study Practice does not require the patients' consent and approval of study protocol by the institutional review board of each participating center, we did not obtain patients' consent.

Patients {#jdi13125-sec-0008}
--------

All patients aged ≥65 years with type 2 diabetes mellitus who started to receive tofogliflozin within 3 months of its launch in Japan were enrolled in this study; there were no restrictions on concomitant diseases and concomitant medications.

Data collection and definition {#jdi13125-sec-0009}
------------------------------

The patients were registered through a central registration system, and patients' data were recorded in electronic case report forms. The investigated items included demographic and baseline characteristics, details of tofogliflozin treatment, concomitant antidiabetic treatment, clinical course (vital signs, HbA1c, fasting blood glucose, laboratory tests), adverse events (AE), and ADRs.

ADRs were defined as AEs whose causal relationship with tofogliflozin administration could not be excluded, based on the physician\'s judgment. The ADRs of special interest were defined as polyuria/pollakiuria, volume depletion‐related events, urinary tract infection, genital infection, hypoglycemia, and skin disorders. ADRs were categorized according to the Medical Dictionary for Regulatory Activities/Japanese edition version 18.1.

Statistical analysis {#jdi13125-sec-0010}
--------------------

Based on the information at baseline on the number of concomitant OADs and the use of insulin, we categorized the patients into groups of 0 OAD, one OAD, two OADs, three or more OADs and insulin. The patients who used insulin at baseline were categorized into the insulin group.

The patients' characteristics, concomitant antidiabetic and diuretic treatments at baseline, and safety evaluations (ADRs and ADRs of special interest) were analyzed descriptively using the safety analysis set, which was defined as all patients for whom electronic case report forms were collected, excluding those with no follow‐up visits after baseline and those for whom concomitant pharmacological treatment information was unavailable. Using the χ^2^‐test, ADRs of special interest were analyzed to explore the differences between groups.

Effectiveness analyses were carried out on the effectiveness analysis set, which was defined as all patients in the safety analysis set, excluding those without effectiveness data. The mean values of HbA1c, bodyweight, estimated glomerular filtration rate \[eGFR\] and insulin dose (U/day, in the insulin group) were descriptively summarized. Missing data at 52 weeks were imputed by using the last observation carried forward (LOCF) method. The change from baseline to LOCF data was calculated and tested by one‐sample *t*‐test.

Patients were also categorized by the types of concomitant drugs at baseline, as follows: naïve (patients with no OAD or insulin use), dipeptidyl peptidase‐4 inhibitors (DPP4i), biguanides (BG), sulfonylureas (SU), DPP4i + BG, DPP4i + SU, BG + SU, DPP4i + BG + SU, insulin and other (including all patients that did not belong to the aforementioned groups) groups. ADRs of special interest and effectiveness (HbA1c, bodyweight and eGFR) were analyzed by using the same methods described above.

All statistical tests were two‐sided, with the significance level set at 5%. All analyses were calculated by using SAS^®^ version 9.4 (SAS Institute, Cary, NC, USA) software.

Results {#jdi13125-sec-0011}
=======

Patient disposition and characteristics {#jdi13125-sec-0012}
---------------------------------------

Of the 1,507 patients in the safety analysis set of the previous study[25](#jdi13125-bib-0025){ref-type="ref"}, 10 patients with unavailable concomitant pharmacological treatment information were excluded; thus, the safety analysis set comprised 1,497 patients in the present study. The effectiveness analysis set comprised 1,422 patients. Details of patients' disposition and discontinuation are reported elsewhere[25](#jdi13125-bib-0025){ref-type="ref"}.

The patients' characteristics are shown in Table [1](#jdi13125-tbl-0001){ref-type="table"}. At baseline, 279 patients (18.6%), 405 patients (27.1%), 368 patients (24.6%), 284 patients (19.0%) and 161 patients (10.8%) used 0 OAD, one OAD, two OADs, three or more OADs and insulin, respectively. Overall, 47.6% of patients were men and 52.4% were women. The mean ± standard deviation (SD) age was 72.4 ± 6.0 years, with 33.2% of patients aged ≥75 years. Overall, the mean ± SD values for HbA1c, bodyweight and eGFR were 7.7 ± 1.4%, 66.8 ± 12.4 kg and 68.7 ± 20.2 mL/min/1.73 m^2^, respectively. The baseline characteristics of diabetes duration, kidney function, HbA1c, diabetic complications and cardiovascular disease differed by the number of OADs and the use of insulin; the groups of patients with multiple OADs and insulin were in a worse condition than the groups of patients with no or fewer OADs.

###### 

Patients' characteristics

  Variable                                                          Safety analysis set (*n* = 1,497)                                                                                                         
  ----------------------------------------------------------------- ----------------------------------- ------------- ------------- ------------- ------------- ------------- ----- ------ ----- ------ ----- ------
  Total                                                             1,497                               100           279           18.6          405           27.1          368   24.6   284   19.0   161   10.8
  Sex                                                                                                                                                                                                         
  Male                                                              713                                 47.6          112           40.1          190           46.9          186   50.5   149   52.5   76    47.2
  Female                                                            784                                 52.4          167           59.9          215           53.1          182   49.5   135   47.5   85    52.8
  Age (years)                                                                                                                                                                                                 
  Mean ± SD                                                         72.4 ± 6.0                          73.3 ± 6.3    73.3 ± 6.2    72.1 ± 6.0    71.3 ± 5.4    71.1 ± 5.2                                    
  ≥65 to \<75                                                       1,000                               66.8          177           63.4          242           59.8          256   69.6   207   72.9   118   73.3
  ≥75                                                               497                                 33.2          102           36.6          163           40.2          112   30.4   77    27.1   43    26.7
  Bodyweight (mean ± SD, kg)                                                                                                                                                                                  
  Overall                                                           66.8 ± 12.4                         66.4 ± 12.0   65.2 ± 12.5   67.0 ± 11.7   68.4 ± 13.1   68.3 ± 12.3                                   
  Male                                                              71.0 ± 12.2                         70.0 ± 11.0   69.1 ± 12.4   71.2 ± 11.6   73.1 ± 13.1   71.8 ± 12.1                                   
  Female                                                            62.9 ± 11.3                         63.8 ± 12.1   61.7 ± 11.6   62.6 ± 10.2   62.8 ± 10.7   65.1 ± 11.7                                   
  Diabetes duration (years)                                                                                                                                                                                   
  Mean ± SD                                                         10.8 ± 7.7                          6.0 ± 5.5     8.9 ± 5.9     10.9 ± 7.8    13.2 ± 7.9    16.5 ± 8.1                                    
  \<1                                                               44                                  2.9           27            9.7           6             1.5           8     2.2    3     1.1    0     0.0
  ≥1 to \<10                                                        407                                 27.2          78            28.0          133           32.8          112   30.4   65    22.9   19    11.8
  ≥10                                                               454                                 30.3          30            10.8          102           25.2          111   30.2   126   44.4   85    52.8
  Unknown                                                           592                                 39.5          144           51.6          164           40.5          137   37.2   90    31.7   57    35.4
  Liver function                                                                                                                                                                                              
  Normal                                                            1,230                               82.2          224           80.3          343           84.7          290   78.8   242   85.2   131   81.4
  Dysfunction                                                       224                                 15.0          40            14.3          57            14.1          62    16.8   38    13.4   27    16.8
  Unknown                                                           43                                  2.9           15            5.4           5             1.2           16    4.3    4     1.4    3     1.9
  Kidney function                                                                                                                                                                                             
  Normal                                                            638                                 42.6          163           58.4          169           41.7          147   39.9   95    33.5   64    39.8
  Dysfunction                                                       811                                 54.2          103           36.9          227           56.0          204   55.4   184   64.8   93    57.8
  Unknown                                                           48                                  3.2           13            4.7           9             2.2           17    4.6    5     1.8    4     2.5
  Baseline eGFR (mL/min/1.73 m^2^)                                                                                                                                                                            
  Mean ± SD                                                         68.7 ± 20.2                         67.7 ± 19.4   68.5 ± 20.9   70.1 ± 19.7   68.0 ± 18.8   68.1 ± 22.7                                   
  \<30                                                              17                                  1.1           4             1.4           6             1.5           4     1.1    2     0.7    1     0.6
  ≥30 to \<45                                                       93                                  6.2           17            6.1           22            5.4           20    5.4    20    7.0    14    8.7
  ≥45 to \<60                                                       242                                 16.2          40            14.3          69            17.0          53    14.4   52    18.3   28    17.4
  ≥60 to \<90                                                       589                                 39.3          92            33.0          163           40.2          159   43.2   119   41.9   56    34.8
  ≥90                                                               134                                 9.0           20            7.2           38            9.4           38    10.3   22    7.7    16    9.9
  Unknown                                                           422                                 28.2          106           38.0          107           26.4          94    25.5   69    24.3   46    28.6
  Baseline HbA1c (%)                                                                                                                                                                                          
  Mean ± SD                                                         7.7 ± 1.4                           7.0 ± 1.1     7.5 ± 1.3     7.7 ± 1.3     7.9 ± 1.3     8.5 ± 1.4                                     
  \<6.5                                                             232                                 15.5          86            30.8          68            16.8          46    12.5   26    9.2    6     3.7
  ≥6.5 to \<7.0                                                     240                                 16.0          54            19.4          78            19.3          57    15.5   42    14.8   9     5.6
  ≥7.0 to \<8.0                                                     491                                 32.8          59            21.1          144           35.6          135   36.7   100   35.2   53    32.9
  ≥8.0                                                              441                                 29.5          39            14.0          89            22.0          114   31.0   110   38.7   89    55.3
  Unknown                                                           93                                  6.2           41            14.7          26            6.4           16    4.3    6     2.1    4     2.5
  Concomitant disease                                                                                                                                                                                         
  No                                                                83                                  5.5           32            11.5          24            5.9           17    4.6    7     2.5    3     1.9
  Yes                                                               1,413                               94.4          246           88.2          381           94.1          351   95.4   277   97.5   158   98.1
  Unknown                                                           1                                   0.1           1             0.4           0             0.0           0     0.0    0     0.0    0     0.0
  Diabetic complications                                            460                                 30.7          32            11.5          93            23.0          127   34.5   116   40.8   92    57.1
  Diabetic retinopathy                                              122                                 8.1           4             1.4           18            4.4           24    6.5    36    12.7   40    24.8
  Diabetic nephropathy                                              319                                 21.3          26            9.3           65            16.0          88    23.9   86    30.3   54    33.5
  Diabetic neuropathy                                               181                                 12.1          9             3.2           25            6.2           47    12.8   54    19.0   46    28.6
  Liver disease                                                     241                                 16.1          39            14.0          66            16.3          62    16.8   44    15.5   30    18.6
  Kidney disease                                                    161                                 10.8          31            11.1          48            11.9          38    10.3   23    8.1    21    13.0
  Cardiovascular disease[^†^](#jdi13125-note-0001){ref-type="fn"}   326                                 21.8          39            14.0          86            21.2          85    23.1   54    19.0   62    38.5
  Cardiovascular disease                                            276                                 18.4          32            11.5          67            16.5          73    19.8   49    17.3   55    34.2
  Cerebrovascular disease                                           74                                  4.9           8             2.9           26            6.4           20    5.4    9     3.2    11    6.8
  Heart failure                                                     108                                 7.2           17            6.1           26            6.4           29    7.9    16    5.6    20    12.4
  Malignancy                                                        21                                  1.4           3             1.1           6             1.5           7     1.9    2     0.7    3     1.9
  Urinary tract infection                                           8                                   0.5           1             0.4           2             0.5           3     0.8    0     0.0    2     1.2
  Hypertension                                                      1,112                               74.3          200           71.7          312           77.0          277   75.3   202   71.1   121   75.2
  Dyslipidemia                                                      1,062                               70.9          174           62.4          279           68.9          262   71.2   227   79.9   120   74.5
  Gout                                                              40                                  2.7           10            3.6           11            2.7           9     2.4    10    3.5    0     0.0
  Hyperuricemia                                                     190                                 12.7          44            15.8          50            12.3          45    12.2   35    12.3   16    9.9
  Osteoporosis                                                      174                                 11.6          42            15.1          62            15.3          38    10.3   18    6.3    14    8.7

The groups are categorized by the numbers of concomitant oral antidiabetic drugs (OADs) and the use of insulin at baseline. ^†^Concomitant cardiovascular disease or medical history of cardiovascular disease. eGFR, estimated glomerular filtration rate; SD, standard deviation.

John Wiley & Sons, Ltd

Concomitant antidiabetic and diuretic treatments at baseline are summarized in Table [2](#jdi13125-tbl-0002){ref-type="table"}. Overall, 81.6% of the patients received concomitant antidiabetic drugs at baseline. The most commonly used OADs were DPP4i (62.0%), SU (32.5%) and BG (26.7%). In the insulin group, 126 patients (78.3%) concomitantly used OADs at baseline: 37.3, 37.3, 22.2 and 3.2% of the patients used one, two, three and four OADs, respectively. Diuretics were concomitantly used by 12.6% of the patients at baseline.

###### 

Concomitant antidiabetic and diuretic treatment at baseline

  Variable                                            Safety analysis set (*n* = 1,497)                                                                                            
  --------------------------------------------------- ----------------------------------- ------ ----------- ----------- ----------- ----------- ----- ------ ------ ------ ------ -------
  No. OADs                                                                                                                                                                         
  Mean ± SD                                           2.0 ± 1.0                           --     1.0 ± 0.0   2.0 ± 0.0   3.3 ± 0.5   1.9 ± 0.8                                     
  1                                                   452                                 38.2   0           405         100         0           0     0      0      47     37.3   
  2                                                   415                                 35.1   0           0           0           368         100   0      0      47     37.3   
  3                                                   229                                 19.4   0           0           0           0           0     201    70.8   28     22.2   
  4                                                   78                                  6.6    0           0           0           0           0     74     26.1   4      3.2    
  5                                                   9                                   0.8    0           0           0           0           0     9      3.2    0      0      
  Class of OADs, insulin and GLP‐1 receptor agonist                                                                                                                                
  Biguanide                                           400                                 26.7   0           0           45          11.1        111   30.2   182    64.1   62     38.5
  Sulfonylurea                                        486                                 32.5   0           0           69          17.0        171   46.5   221    77.8   25     15.5
  DPP4 inhibitor                                      928                                 62.0   0           0           263         64.9        307   83.4   269    94.7   89     55.3
  Fast‐acting insulin secretagogue                    45                                  3.0    0           0           3           0.7         17    4.6    20     7.0    5      3.1
  α‐Glucosidase inhibitor                             206                                 13.8   0           0           18          4.4         51    13.9   98     34.5   39     24.2
  Thiazolidinedione                                   261                                 17.4   0           0           7           1.7         79    21.5   154    54.2   21     13.0
  Insulin                                             161                                 10.8   0           0           0           0           0     0      0      0      161    100.0
  GLP‐1 receptor agonist                              22                                  1.5    4           1.4         8           2.0         4     1.1    2      0.7    4      2.5
  Concomitant diuretics at baseline                                                                                                                                                
  No                                                  1,308                               87.4   254         91.0        359         88.6        327   88.9   239    84.2   129    80.1
  Yes                                                 189                                 12.6   25          9.0         46          11.4        41    11.1   45     15.8   32     19.9
  Class of diuretics                                                                                                                                                               
  Loop diuretics                                      64                                  4.3    10          3.6         16          4.0         17    4.6    12     4.2    9      5.6
  Thiazides                                           84                                  5.6    12          4.3         21          5.2         17    4.6    15     5.3    19     11.8
  Anti‐aldosterone                                    41                                  2.7    6           2.2         12          3.0         4     1.1    11     3.9    8      5.0
  Other diuretics                                     21                                  1.4    1           0.4         3           0.7         6     1.6    10     3.5    1      0.6

The groups are categorized by the numbers of concomitant oral antidiabetic drugs (OADs) and the use of insulin at baseline. DPP4, dipeptidyl peptidase‐4; GLP‐1, glucagon‐like peptide‐1; SD, standard deviation.

John Wiley & Sons, Ltd

The mean ± SD total insulin dose in the insulin group (*n* = 148) was 30.55 ± 30.77 U at baseline, and 29.33 ± 30.52 U at 52‐week LOCF, with the mean ± SD change as −1.22 ± 7.11 U (*P* = 0.039) from baseline to 52‐week LOCF (Table [S1](#jdi13125-sup-0002){ref-type="supplementary-material"}).

Safety {#jdi13125-sec-0013}
------

Overall, 271 patients (18.10%) and 33 patients (2.20%) experienced ADRs and serious ADRs, respectively (Table [3](#jdi13125-tbl-0003){ref-type="table"}). ADRs of special interest in the total, 0 OAD, one OAD, two OADs, three or more OADs and insulin groups were observed in 183 patients (12.22%), 28 patients (10.04%), 50 patients (12.35%), 49 patients (13.32%), 32 patients (11.27%) and 24 patients (14.91%), respectively. Overall, volume depletion‐related events were the most frequently observed ADRs of special interest (59 patients, 3.94%), followed by polyuria/pollakiuria (44 patients, 2.94%) and skin disorders (36 patients, 2.40%). Hypoglycemia occurred in 16 patients (1.07%).

###### 

Adverse drug reactions and adverse drug reactions of special interest

  ADRs                                  Safety analysis set (*n* = 1,497)                                                                            
  ------------------------------------- ----------------------------------- ------- ---- ------- ---- ------- ---- ------- ---- ------- ---- ------- --------
  ADRs                                  271                                 18.10   37   13.26   72   17.78   74   20.11   55   19.37   33   20.50   
  Serious ADRs                          33                                  2.20    4    1.43    9    2.22    10   2.72    6    2.11    4    2.48    
  ADRs of special interest              183                                 12.22   28   10.04   50   12.35   49   13.32   32   11.27   24   14.91   
  Hypoglycemia                          16                                  1.07    1    0.36    1    0.25    3    0.82    5    1.76    6    3.73    0.0028
  Polyuria/pollakiuria                  44                                  2.94    8    2.87    10   2.47    11   2.99    8    2.82    7    4.35    0.8343
  Pollakiuria                           33                                  2.20    6    2.15    8    1.98    7    1.90    6    2.11    6    3.73    
  Nocturia                              12                                  0.80    1    0.36    2    0.49    3    0.82    4    1.41    2    1.24    
  Polyuria                              8                                   0.53    3    1.08    0    0       3    0.82    1    0.35    1    0.62    
  Volume depletion‐related events       59                                  3.94    9    3.23    18   4.44    16   4.35    10   3.52    6    3.73    0.9157
  Dehydration                           25                                  1.67    5    1.79    7    1.73    7    1.90    3    1.06    3    1.86    
  Constipation                          11                                  0.73    1    0.36    3    0.74    4    1.09    3    1.06    0    0       
  Thirst                                9                                   0.60    1    0.36    3    0.74    2    0.54    2    0.70    1    0.62    
  Blood urea increased                  6                                   0.40    1    0.36    1    0.25    1    0.27    2    0.70    1    0.62    
  Cerebral infarction                   3                                   0.20    0    0       0    0       3    0.82    0    0       0    0       
  Hemoconcentration                     2                                   0.13    0    0       1    0.25    0    0       0    0       1    0.62    
  Loss of consciousness                 2                                   0.13    1    0.36    0    0       0    0       0    0       1    0.62    
  Lacunar infarction                    2                                   0.13    0    0       0    0       0    0       1    0.35    1    0.62    
  Depressed level of consciousness      1                                   0.07    0    0       1    0.25    0    0       0    0       0    0       
  Diverticulum intestinal hemorrhagic   1                                   0.07    1    0.36    0    0       0    0       0    0       0    0       
  Ketoacidosis                          1                                   0.07    0    0       1    0.25    0    0       0    0       0    0       
  Syncope                               1                                   0.07    0    0       1    0.25    0    0       0    0       0    0       
  Heat illness                          1                                   0.07    0    0       0    0       1    0.27    0    0       0    0       
  Urinary tract infection               31                                  2.07    8    2.87    6    1.48    11   2.99    3    1.06    3    1.86    0.3341
  Cystitis                              16                                  1.07    2    0.72    3    0.74    6    1.63    3    1.06    2    1.24    
  Urinary tract infection               10                                  0.67    6    2.15    1    0.25    2    0.54    1    0.35    0    0       
  Pyelonephritis                        3                                   0.20    0    0       1    0.25    1    0.27    0    0       1    0.62    
  Cystitis hemorrhagic                  2                                   0.13    0    0       1    0.25    1    0.27    0    0       0    0       
  Pyelonephritis acute                  2                                   0.13    0    0       0    0       1    0.27    0    0       1    0.62    
  Septic shock                          1                                   0.07    0    0       0    0       1    0.27    0    0       0    0       
  Genital infection                     20                                  1.34    4    1.43    5    1.23    5    1.36    4    1.41    2    1.24    0.9993
  Pruritus genital                      9                                   0.60    3    1.08    3    0.74    1    0.27    2    0.70    0    0       
  Genital infection                     4                                   0.27    0    0       1    0.25    1    0.27    2    0.70    0    0       
  Vulvovaginal candidiasis              3                                   0.20    0    0       0    0       2    0.54    0    0       1    0.62    
  Balanoposthitis                       2                                   0.13    0    0       1    0.25    0    0       1    0.35    0    0       
  Vulvitis                              2                                   0.13    0    0       0    0       0    0       1    0.35    1    0.62    
  Genital rash                          1                                   0.07    0    0       0    0       0    0       1    0.35    0    0       
  Vaginal inflammation                  1                                   0.07    1    0.36    0    0       0    0       0    0       0    0       
  Genital infection fungal              1                                   0.07    1    0.36    0    0       0    0       0    0       0    0       
  Genital infection female              1                                   0.07    0    0       0    0       1    0.27    0    0       0    0       
  Skin disorders                        36                                  2.40    3    1.08    15   3.70    6    1.63    7    2.46    5    3.11    0.1782
  Rash                                  11                                  0.73    2    0.72    4    0.99    1    0.27    1    0.35    3    1.86    
  Pruritus                              7                                   0.47    0    0       2    0.49    0    0       4    1.41    1    0.62    
  Drug eruption                         4                                   0.27    0    0       1    0.25    2    0.54    0    0       1    0.62    
  Urticaria                             4                                   0.27    1    0.36    3    0.74    0    0       0    0       0    0       
  Eczema                                3                                   0.20    0    0       1    0.25    0    0       1    0.35    1    0.62    
  Dermatitis allergic                   2                                   0.13    0    0       2    0.49    0    0       0    0       0    0       
  Erythema                              2                                   0.13    0    0       0    0       1    0.27    1    0.35    0    0       
  Rash pruritic                         2                                   0.13    0    0       0    0       0    0       2    0.70    0    0       
  Pruritus generalized                  2                                   0.13    0    0       0    0       2    0.54    0    0       0    0       
  Miliaria                              1                                   0.07    0    0       1    0.25    0    0       0    0       0    0       
  Papule                                1                                   0.07    0    0       1    0.25    0    0       0    0       0    0       
  Rash scarlatiniform                   1                                   0.07    0    0       1    0.25    0    0       0    0       0    0       
  Skin exfoliation                      1                                   0.07    0    0       0    0       0    0       0    0       1    0.62    
  Tinea infection                       1                                   0.07    0    0       1    0.25    0    0       0    0       0    0       

The groups are categorized by the numbers of concomitant oral antidiabetic drugs (OADs) and the use of insulin at baseline. ^†^The χ^2^‐test. Medical Dictionary for Regulatory Activities/Japanese edition version 18.1. ADR, adverse drug reaction.

John Wiley & Sons, Ltd

Of the volume depletion‐related events, dehydration was the most commonly observed, and the incidence did not largely differ between groups (total incidence: 1.67%; incidence range for all groups: 1.06--1.90%). Ketoacidosis occurred in one patient in the one OAD group who was concomitantly taking DPP4i.

Polyuria/pollakiuria incidence was the highest in the insulin group, and the incidences in the other groups were generally similar (the insulin group: 4.35% vs the 0 to ≥3 OADs groups: 2.47--2.99%). Among the polyuria/pollakiuria ADRs of special interest, pollakiuria was the most frequent; furthermore, patients in the insulin group experienced pollakiuria more often (the insulin group: 3.73% vs the 0 to ≥3 OADs groups: 1.90--2.15%).

Among the skin disorders that were defined as the ADRs of special interest, rash occurred most frequently; furthermore, the insulin group experienced rash most frequently (the insulin group: 1.86% vs the 0 to ≥3 OADs groups: 0.27--0.99%).

Overall, 2.07 and 1.34% of patients experienced urinary tract infection and genital infection, respectively. The 0 and two OADs groups experienced comparatively high incidences of urinary tract infection (0 and 2 OADs groups: 2.87 and 2.99% vs the 1 and ≥3 OADs and insulin groups: 1.06--1.86%), whereas no notable difference in genital infection incidence was observed between the groups (all groups: 1.23--1.43%).

Hypoglycemia occurred more often in the groups of three or more OADs and insulin than in the groups of 0 or fewer OADs (the ≥3 OADs and insulin groups: 1.76 and 3.73% vs the 0 to 2 OADs groups: 0.25--0.82%). Severe hypoglycemia was not reported.

Effectiveness {#jdi13125-sec-0014}
-------------

The results of HbA1c, bodyweight, and eGFR for each group are shown in Figure [1](#jdi13125-fig-0001){ref-type="fig"} and Table [4](#jdi13125-tbl-0004){ref-type="table"}. HbA1c and bodyweight decreased from baseline to LOCF in all groups.

![Plot of mean values of (a) glycated hemoglobin (HbA1c), (b) bodyweight and (c) estimated glomerular filtration rate (eGFR) by visit. The groups are categorized by the number of concomitant oral antidiabetic drug (OADs) and the use of insulin at baseline (BL).](JDI-11-405-g001){#jdi13125-fig-0001}

###### 

Mean values and changes in glycated hemoglobin, bodyweight and estimated glomerular filtration rate

  Variable                                                                                       Effectiveness analysis set (*n* = 1,422)                                                                                                                                                                        
  ---------------------------------------------------------------------------------------------- ------------------------------------------ ---------------- --------------- ---------------- --------------- ---------------- --------------- ---------------- --------------- ---------------- --------------- -----
  HbA1c (%)                                                                                                                                                                                                                                                                                                      
  Baseline                                                                                       7.64 ± 1.35                                1,345            7.00 ± 1.12     228              7.48 ± 1.28     368              7.73 ± 1.32     333              7.88 ± 1.34     266              8.43 ± 1.40     150
  Week 4                                                                                         7.44 ± 1.24                                1,101            6.93 ± 1.15     161              7.40 ± 1.29     292              7.42 ± 1.17     286              7.54 ± 1.16     233              8.06 ± 1.24     129
  Week 12                                                                                        7.21 ± 1.07                                1,150            6.79 ± 0.92     198              7.17 ± 1.07     311              7.18 ± 0.98     291              7.34 ± 1.07     228              7.83 ± 1.20     122
  Week 24                                                                                        7.16 ± 1.01                                903              6.73 ± 0.93     143              7.02 ± 0.85     251              7.13 ± 0.94     230              7.33 ± 1.02     179              7.85 ± 1.23     100
  Week 36                                                                                        7.19 ± 1.12                                832              6.65 ± 0.82     132              7.02 ± 0.92     225              7.15 ± 1.00     214              7.47 ± 1.35     171              7.97 ± 1.18     90
  Week 52                                                                                        7.04 ± 1.01                                816              6.50 ± 0.62     131              6.87 ± 0.78     230              7.06 ± 0.94     208              7.27 ± 1.12     165              7.90 ± 1.28     82
  LOCF                                                                                           7.17 ± 1.16                                1,402            6.66 ± 0.95     252              7.05 ± 1.09     383              7.14 ± 1.06     346              7.38 ± 1.18     271              7.98 ± 1.34     150
  Change from baseline to LOCF, mean ± SD (*P*‐value[^†^](#jdi13125-note-0004){ref-type="fn"})   −0.46 ± 1.02                               1,327            −0.34 ± 0.91    222              −0.42 ± 1.06    362              −0.56 ± 1.03    330              −0.50 ± 1.07    265              −0.44 ± 0.89    148
  (*P* \< 0.001)                                                                                                                            (*P* \< 0.001)                   (*P* \< 0.001)                   (*P* \< 0.001)                   (*P* \< 0.001)                   (*P* \< 0.001)                   
  Bodyweight (kg)                                                                                                                                                                                                                                                                                                
  Baseline                                                                                       67.44 ± 12.52                              1,036            67.20 ± 12.19   160              65.44 ± 12.03   276              68.02 ± 11.71   251              68.49 ± 13.45   222              69.10 ± 13.45   127
  Week 4                                                                                         66.25 ± 12.44                              925              65.73 ± 12.12   134              64.42 ± 12.48   245              66.85 ± 11.95   230              67.38 ± 13.34   197              67.59 ± 11.83   119
  Week 12                                                                                        65.63 ± 12.37                              907              64.68 ± 12.05   141              63.39 ± 12.26   245              66.20 ± 11.92   229              67.64 ± 13.27   185              67.32 ± 11.68   107
  Week 24                                                                                        65.42 ± 11.88                              680              64.90 ± 11.43   96               63.54 ± 11.60   186              66.21 ± 11.85   175              66.91 ± 12.92   142              66.03 ± 10.86   81
  Week 36                                                                                        65.71 ± 11.78                              580              65.31 ± 11.67   77               64.08 ± 11.41   153              66.18 ± 11.75   150              67.48 ± 13.02   122              65.63 ± 10.37   78
  Week 52                                                                                        64.88 ± 11.97                              598              63.71 ± 12.49   86               63.48 ± 11.76   163              65.54 ± 11.54   161              66.43 ± 12.75   121              65.44 ± 11.15   67
  LOCF                                                                                           64.68 ± 12.12                              1,122            63.32 ± 11.69   172              62.68 ± 11.83   309              65.47 ± 11.93   274              66.05 ± 12.85   234              67.03 ± 11.70   133
  Change from baseline to LOCF, mean ± SD (*P*‐value[^†^](#jdi13125-note-0004){ref-type="fn"})   −2.72 ± 3.59                               994              −3.11 ± 3.75    151              −2.61 ± 3.18    261              −2.65 ± 3.10    243              −2.61 ± 3.35    217              −2.77 ± 5.18    122
  (*P* \< 0.001)                                                                                                                            (*P* \< 0.001)                   (*P* \< 0.001)                   (*P* \< 0.001)                   (*P* \< 0.001)                   (*P* \< 0.001)                   
  eGFR (mL/min/1.73 m^2^)                                                                                                                                                                                                                                                                                        
  Baseline                                                                                       68.81 ± 20.14                              1,028            68.17 ± 19.23   164              68.50 ± 20.83   289              70.54 ± 19.85   259              68.29 ± 18.65   206              67.43 ± 22.90   110
  Week 4                                                                                         65.11 ± 19.17                              770              64.91 ± 17.79   98               64.52 ± 19.24   216              66.40 ± 18.79   205              65.65 ± 16.49   158              62.88 ± 24.83   93
  Week 12                                                                                        67.58 ± 20.39                              823              68.68 ± 19.06   130              67.88 ± 23.10   227              68.32 ± 18.90   208              65.70 ± 17.12   172              67.13 ± 24.10   86
  Week 24                                                                                        69.66 ± 25.72                              651              69.49 ± 17.38   96               69.04 ± 22.11   197              69.88 ± 19.70   162              68.48 ± 16.32   136              74.02 ± 59.03   60
  Week 36                                                                                        69.70 ± 21.24                              605              71.46 ± 21.61   87               69.06 ± 23.82   162              71.16 ± 20.41   165              67.22 ± 17.01   133              70.40 ± 24.04   58
  Week 52                                                                                        68.83 ± 21.37                              566              69.38 ± 17.90   86               68.30 ± 21.37   169              69.03 ± 19.07   149              68.00 ± 17.41   113              70.97 ± 37.05   49
  LOCF                                                                                           68.09 ± 24.02                              1,202            69.30 ± 19.72   202              67.54 ± 23.22   335              69.05 ± 19.87   297              66.88 ± 16.39   242              67.62 ± 44.93   126
  Change from baseline to LOCF, mean ± SD (*P*‐value[^†^](#jdi13125-note-0004){ref-type="fn"})   −0.64 ± 10.89                              967              −0.17 ± 11.26   148              −0.21 ± 11.13   271              −0.41 ± 9.49    245              −1.41 ± 9.27    198              −1.47 ± 14.99   105
  (*P* = 0.070)                                                                                                                             (*P* = 0.858)                    (*P* = 0.757)                    (*P* = 0.498)                    (*P* = 0.034)                    (*P* = 0.318)                    

The groups are categorized by the numbers of concomitant oral antidiabetic drug (OADs) and use of insulin at baseline. ^†^One‐sample *t*‐test. eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; LOCF, last observation carried forward analysis; SD, standard deviation.

John Wiley & Sons, Ltd

The mean ± SD HbA1c (%) at baseline and LOCF, and the mean ± SD change from baseline to LOCF were 7.64 ± 1.35, 7.17 ± 1.16 and −0.46 ± 1.02 (*P* \< 0.001) in the total group. The mean ± SD baseline HbA1c (%) was 7.00 ± 1.12, 7.48 ± 1.28, 7.73 ± 1.32, 7.88 ± 1.34 and 8.43 ± 1.40 in the 0 OAD, one OAD, two OADs, three or more OADs and insulin groups, respectively. The mean ± SD (%) change was −0.34 ± 0.91, −0.42 ± 1.06, −0.56 ± 1.03, −0.50 ± 1.07 and −0.44 ± 0.89 in the 0 OAD, one OAD, two OADs, three or more OADs and insulin groups, respectively (*P* \< 0.001 for all).

As for the bodyweight, the mean ± SD (kg) at baseline and LOCF, and the mean ± SD change from baseline to LOCF were 67.44 ± 12.52, 64.68 ± 12.12 and −2.72 ± 3.59 (*P* \< 0.001) overall. The mean ± SD (kg) change from baseline to LOCF was −3.11 ± 3.75, −2.61 ± 3.18, −2.65 ± 3.10, −2.61 ± 3.35 and −2.77 ± 5.18 in the 0 OAD, one OAD, two OADs, three or more OADs and insulin groups, respectively (*P* \< 0.001 for all).

The mean ± SD eGFR (mL/min/1.73 m^2^) at baseline and LOCF, and the mean ± SD change from baseline to LOCF were 68.81 ± 20.14, 68.09 ± 24.02 and −0.64 ± 10.89 (*P* = 0.070), respectively. The mean ± SD (mL/min/1.73 m^2^) change from baseline to LOCF was −0.17 ± 11.26 (*P* = 0.858), −0.21 ± 11.13 (*P* = 0.757), −0.41 ± 9.49 (*P* = 0.498), −1.41 ± 9.27 (*P* = 0.034) and −1.47 ± 14.99 (*P* = 0.318) in the 0 OAD, one OAD, two OADs, three or more OADs and insulin groups, respectively.

Safety and effectiveness by types of concomitant drugs at baseline {#jdi13125-sec-0015}
------------------------------------------------------------------

The ADRs of special interest and effectiveness by types of concomitant drugs at baseline are available as supplementary information. In all groups, the ADRs of special interest, HbA1c, bodyweight and eGFR results were generally similar (Table [S2](#jdi13125-sup-0002){ref-type="supplementary-material"}; Figure [S1](#jdi13125-sup-0001){ref-type="supplementary-material"}). Hypoglycemia did not occur in the patients with concomitant SU use at baseline (Table [S2](#jdi13125-sup-0002){ref-type="supplementary-material"}).

Discussion {#jdi13125-sec-0016}
==========

We carried out a 1‐year post‐marketing study of tofogliflozin among elderly Japanese patients with type 2 diabetes mellitus aged ≥65 years, and have previously reported the overall results[24](#jdi13125-bib-0024){ref-type="ref"}, [25](#jdi13125-bib-0025){ref-type="ref"}. The present subanalysis study aimed to further assess the safety and effectiveness of tofogliflozin, by categorizing the patients by the number of OADs and the use of insulin at baseline. ADRs of special interest in the total, 0 OAD, one OAD, two OADs, three or more OADs and insulin groups were observed in 12.22% of patients, with 10.04, 12.35, 13.32, 11.27 and 14.91% of patients in each group, respectively. Overall, HbA1c and bodyweight significantly decreased (−0.46% and −2.72 kg, respectively) whereas eGFR did not significantly change (−0.64 mL/min/1.73 m^2^).

Overall, the safety profile of tofogliflozin in the present study was similar to that reported in other 1‐year SGLT2 inhibitor post‐marketing studies of elderly Japanese patients with type 2 diabetes mellitus (e.g., ADR incidence was 18.10% in this study vs 9.09--16.91% in other post‐marketing studies)[26](#jdi13125-bib-0026){ref-type="ref"}, [27](#jdi13125-bib-0027){ref-type="ref"}, [28](#jdi13125-bib-0028){ref-type="ref"}, [29](#jdi13125-bib-0029){ref-type="ref"}, [30](#jdi13125-bib-0030){ref-type="ref"}. A 1‐year dapagliflozin post‐marketing study in elderly Japanese patients with type 2 diabetes mellitus reported that ADRs occurred in 9.5, 11.2, 16.7 and 12.8% in the groups of the patients using 0 AD, one AD, two ADs and three or more ADs, respectively[27](#jdi13125-bib-0027){ref-type="ref"}. Even though the direct comparison with this study is limited by the differences in group categorization (i.e., the previous study\'s "antidiabetic drug group" included insulin and glucagon‐like peptide 1), the results were not considerably different. In line with other SGLT2 inhibitor post‐marketing studies, we confirmed the safety of tofogliflozin in real‐world settings among elderly patients.

Elderly patients might be unaware of the symptoms of ADRs of tofogliflozin, such as hypoglycemia and dehydration. In the present study, hypoglycemia occurred in a total of 1.07% of the patients, which was generally consistent with previous studies (0.22--0.68% in other post‐marketing studies)[26](#jdi13125-bib-0026){ref-type="ref"}, [27](#jdi13125-bib-0027){ref-type="ref"}, [28](#jdi13125-bib-0028){ref-type="ref"}, [29](#jdi13125-bib-0029){ref-type="ref"}, [30](#jdi13125-bib-0030){ref-type="ref"}. The incidence of hypoglycemia was highest in the insulin group (3.73% in the insulin group vs 0.25--1.76% in the other groups), which is obvious, because insulins are associated with the risk of hypoglycemia[31](#jdi13125-bib-0031){ref-type="ref"}, [32](#jdi13125-bib-0032){ref-type="ref"}. Compared with other classes of drugs and basal insulin, a meta‐analysis found that SGLT2 inhibitors, for monotherapy in particular, were less associated with hypoglycemia in patients with type 2 diabetes mellitus[33](#jdi13125-bib-0033){ref-type="ref"}. Dehydration was experienced by 1.67% of the patients, and this value is generally comparable with other post‐marketing studies (0.58--0.8%)[26](#jdi13125-bib-0026){ref-type="ref"}, [27](#jdi13125-bib-0027){ref-type="ref"}, [28](#jdi13125-bib-0028){ref-type="ref"}, [29](#jdi13125-bib-0029){ref-type="ref"}. With these points in mind, appropriate insulin reduction for preventing hypoglycemia, and proper instruction on sufficient liquid intake for preventing dehydration are essential for treating elderly patients with tofogliflozin. Continuous safety investigation of tofogliflozin is indeed required.

The combined use of DPP4i and SU has been reported to increase the risk of hypoglycemia[34](#jdi13125-bib-0034){ref-type="ref"}. In the present study, an increase in the incidence of hypoglycemia was not seen in patients with concomitant tofogliflozin and SU use at baseline (0 patients reporting hypoglycemia). This might be attributed to the recommendation for SGLT2 inhibitor use, which requires careful attention to hypoglycemia when using SGLT2 inhibitors concomitantly with SU. However, this result should be interpreted with care owing to the possible effects of other concomitant drugs and the relatively small number of patients in the SU group (*n* = 69).

The incidence of other ADRs of special interest in the present study was consistent with that reported in other post‐marketing studies (3.94% vs 0.73--3.13% for volume depletion‐related events, 2.94% vs 1.2--4.62% for polyuria/pollakiuria, 2.07% vs 0.67--1.74% for urinary tract infection, 1.34% vs 0.65--1.95% for genital infection and 2.40% vs 1.17--3.16% for skin disorders in this study vs other post‐marketing studies)[26](#jdi13125-bib-0026){ref-type="ref"}, [27](#jdi13125-bib-0027){ref-type="ref"}, [28](#jdi13125-bib-0028){ref-type="ref"}, [29](#jdi13125-bib-0029){ref-type="ref"}, [30](#jdi13125-bib-0030){ref-type="ref"}. Considering the number of OADs and insulin use in the present study, the incidence of volume depletion‐related events and genital infections was not substantially different, whereas incidences of polyuria/pollakiuria, urinary tract infection and skin disorders varied slightly.

For effectiveness, HbA1c and bodyweight were decreased by −0.46% and −2.72 kg from baseline to LOCF, with no notable differences between groups; the overall changes in HbA1c and bodyweight were consistent with those seen in other post‐marketing studies (HbA1c change as −0.44 to −0.77%, bodyweight change as −2.41 to −2.91 kg, respectively, in other post‐marketing studies)[26](#jdi13125-bib-0026){ref-type="ref"}, [27](#jdi13125-bib-0027){ref-type="ref"}, [28](#jdi13125-bib-0028){ref-type="ref"}, [29](#jdi13125-bib-0029){ref-type="ref"}, [30](#jdi13125-bib-0030){ref-type="ref"}. It is of note that bodyweight decreased after tofogliflozin administration even in the insulin group, although insulin administration usually leads to weight gain[35](#jdi13125-bib-0035){ref-type="ref"}.

In the present study, the mean baseline eGFR and its change from baseline to LOCF were 68.81 and −0.64 mL/min/1.73 m^2^, respectively. These results are in agreement with other post‐marketing studies, with the mean baseline eGFR as 67.86--69.7 mL/min/1.73 m^2^ and its change from baseline to final observation as −0.85 to −1.0 mL/min/1.73 m^2^ [26](#jdi13125-bib-0026){ref-type="ref"}, [28](#jdi13125-bib-0028){ref-type="ref"}. Tofogliflozin administration should be avoided for patients with severe renal impairment, as instructed in the package insert, because tofogliflozin might not be effective for such patients. Previous SGLT2 inhibitor studies reported a compromised HbA1c‐lowering effect in patients with moderate renal impairment (eGFR 30 to \<60 mL/min/1.73 m^2^)[36](#jdi13125-bib-0036){ref-type="ref"}, [37](#jdi13125-bib-0037){ref-type="ref"}. Levels of eGFR should be taken into consideration before tofogliflozin administration, with its careful monitoring particularly for patients with renal impairment.

In Japan, tofogliflozin is rarely used as a first‐line type 2 diabetes mellitus treatment. Patients in the present study also concomitantly used other OADs, such as DPP4i, SU and insulin at baseline. As discussed above, we found no peculiar ADRs or substantial increase in ADRs of special interest, accompanied with HbA1c and bodyweight reduction effects across all groups of elderly patients with type 2 diabetes mellitus in Japan. Although it is essential to accumulate more safety data of tofogliflozin, considering that elderly patients might not recognize the symptoms, such as hypoglycemia and dehydration, the present findings suggest tofogliflozin as another safe and effective first‐line and additional treatment for elderly patients in Japan.

Although tofogliflozin may be used safely and effectively, irrespective of the number of OADs, the avoidance of polypharmacy should be sought wherever possible when treating elderly patients with type 2 diabetes mellitus. As mentioned in the Introduction, polypharmacy increases the risk of adverse drug events[8](#jdi13125-bib-0008){ref-type="ref"}, [9](#jdi13125-bib-0009){ref-type="ref"} (e.g., dementia[38](#jdi13125-bib-0038){ref-type="ref"}), drug--drug interactions[10](#jdi13125-bib-0010){ref-type="ref"}, [11](#jdi13125-bib-0011){ref-type="ref"}, falls[6](#jdi13125-bib-0006){ref-type="ref"}, [12](#jdi13125-bib-0012){ref-type="ref"} and treatment costs[13](#jdi13125-bib-0013){ref-type="ref"}. Furthermore, polypharmacy can result in low adherence to medication[6](#jdi13125-bib-0006){ref-type="ref"}, [39](#jdi13125-bib-0039){ref-type="ref"}. The present study results partially support the previous findings, as relatively high incidences of ADRs were found in the groups with multiple OAD use (i.e., the 1 OAD, 2 OADs and ≥3 OADs groups) than in the 0 OAD group. For instance, hypoglycemia was slightly higher in the three or more OADs group than in the groups with no or fewer OADs. Polypharmacy might be inevitable for some elderly patients with type 2 diabetes mellitus for the management of their comorbidities and diabetic complications. However, considering the risks of polypharmacy, simple type 2 diabetes mellitus treatment might be the key for optimal, safe and beneficial management. Tofogliflozin could contribute to a simple therapeutic strategy for elderly patients with type 2 diabetes mellitus, as its safety and effectiveness were confirmed to be unrelated to the number of OADs and the use of insulin in the present study.

Some limitations of this study should be acknowledged. First, the study population might have been in better health than the general elderly Japanese population with type 2 diabetes mellitus, as this study was carried out before the revised recommendation for SGLT2 inhibitor use in 2016. Because a wider range of elderly patients had been advised of the careful use of SGLT2 inhibitors before the revision of recommendation in 2016, the investigators in the present study might have carefully chosen the elderly patients in better physical condition for the administration of tofogliflozin; for example, patients with a relatively high bodyweight. Second, the present subanalysis categorized the patients based on the number and type of drugs at baseline, and did not take into consideration the effects on patients who added or reduced their concomitant drugs during the study. Third, owing to the nature of this study, the effects of treatment on patients cannot be solely attributable to tofogliflozin. Fourth, hypoglycemia incidence might have been underestimated in this study, as elderly patients are more likely to be unaware of hypoglycemia events[5](#jdi13125-bib-0005){ref-type="ref"}, [40](#jdi13125-bib-0040){ref-type="ref"}. Finally, further studies over a longer duration are warranted to explore the safety and effectiveness of tofogliflozin in elderly Japanese patients.

In conclusion, the present findings suggest that tofogliflozin can be safely and effectively used by elderly Japanese patients with type 2 diabetes mellitus, irrespective of the number of OADs and the use of insulin, as no peculiar ADRs or substantial increase in ADRs of special interest were observed across groups, and HbA1c and bodyweight were decreased in all groups.
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**Figure S1** \| Changes in glycated hemoglobin, bodyweight and estimated glomerular filtration rate by the type of concomitant drugs at baseline, from baseline to the 52‐week last observation carried forward.
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**Table S1** \| Insulin dose in the insulin group at each study point (effectiveness analysis set).

**Table S2** \| Adverse drug reactions of special interest presented by the concomitant drug type at baseline.
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